JNJ
Poolbeg Pharma PLC (AIM: POLB, OTC: POLBF, FRA:POLBF) received UK regulatory clearance for its TOPICAL...
Article Summary
HOLD- Poolbeg Pharma PLC (AIM: POLB, OTC: POLBF, FRA:POLBF) received UK regulatory clearance for its TOPICAL trial, with interim data expected this summer for POLB 001, a potential first-approved preventative therapy for CRS, a serious immune reaction triggered by cancer immunotherapies including CAR T-cell therapies and bispecific antibodies.
- The AIM-listed clinical-stage biopharmaceutical company received clinical trial authorisation from the UK Medicines and Healthcare products Regulatory Agency for the TOPICAL study, which will enrol around 30 relapsed or refractory multiple myeloma patients receiving teclistamab from Johnson & Johnson at no cost.
- The trial now spans six UK sites including The Christie, The Royal Marsden, University College London Hospitals, University Hospitals Birmingham, NHS Lothian in Edinburgh, and Royal Stoke University Hospital, with site initiation visits scheduled and patient screening set to commence shortly.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 6.1% | 25% | 35.0 ptsBelow Screener (6.1%) - Weak growth |
| EPS Growth Next 5Y ? | 8.9% | 25% | 20.0 ptsWeak (8.9%) - Low expectations |
| Target Price Upside ? | 6.5% | 20% | 35.0 ptsBelow Screener (6.5%) - Target: $255.26 vs Current: $239.74 |
| Gross Margin % ? | 68.0% | 15% | 80.0 ptsVery Healthy (68.0%) - High-quality margins |
| Drawdown from 52-Wk High ? | -4.8% | 15% | 20.0 ptsBarely a Dip (-4.8%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About JNJ
- Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
- It operates in two segments, Innovative Medicine and MedTech.
- The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
- The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
- This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand.
- The company was founded in 1886 and is based in New Brunswick, New Jersey.